Waddah Arafat

机构：Southwestern Medical Center, Southwestern Medical Center, The University of Texas Southwestern Medical Center · ORCID：0000-0002-6057-2348

发表论文 58 篇 · 总被引 492 次 · h-index 11

代表论文

• Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial (2025 · Annals of Oncology · 被引 68)
• EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). (2025 · Journal of Clinical Oncology · 被引 19)
• Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (2025 · ESMO Open · 被引 17)
• Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). (2025 · Journal of Clinical Oncology · 被引 7)
• Clinical Outcomes of Patients With Metastatic Prostate Cancer With Microsatellite Instability Treated With Pembrolizumab (2025 · Clinical Genitourinary Cancer · 被引 2)
• ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs). (2025 · Journal of Clinical Oncology · 被引 2)